Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers April 21, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - April 21, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/20/14 - FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA CardioCell LLC has just received the FDA's investigational new drug approval for a United States- based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure, which generates more than 1 million hospitalizations annually.
4/20/14 - Patent Issued for Glucagon Analogues
By a News Reporter-Staff News Editor at Heart Disease Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Meier, Eddi; Riber, Ditte; Skovgaard, Marie; Larsen, Bjarne Due; Daugaard, Jens Rosengren, filed on December 15, 2008, was published online on April 1, 2014. The patent's assignee for patent number 86859
4/20/14 - Researchers divided over effectiveness of hyperbaric oxygen for traumatic brain injury treatment [The Oklahoman, Oklahoma City :: ]
April 20 Two years ago, Oklahoma National Guard Capt. Matt Smothermon spent months trying to write a single page that would get him back into law school. But the therapy, commonly used to treat divers with decompression sickness, hasn't received FDA approval for the treatment of brain injury.
4/19/14 - DrugNews: Court Records Show Rising Lawsuits for Pradaxa as Additional Uses Approved
Pradaxa was approved by the FDA in 2010 to prevent blood clots and strokes in patients with atrial fibrillation. The Institute for Safe Medication Practices has also advised bleeding from Pradaxa could be 5 times as likely to cause death***. Now, DrugNews has learned the FDA has approved the usage of Pradaxa for DVT and pulmonary embolism, in addit
4/19/14 - India : FUNDING and grant secured by Lincoln pharmaceutical company [TendersInfo (India)]
Ground Fluor Pharmaceuticals Inc. declared that a vote of confidence from the National Science Foundation helped a Lincoln- based medical technology startup company attract and close its first round of funding. Cambridge, Mass.- based Cedarville Investments Ltd. has put in in the specialty pharmaceutical company, which has developed a new way to pr
4/19/14 - Particle Sciences and Actavis Enter into Joint Development Agreement
By a News Reporter-Staff News Editor at Marketing Weekly News Particle Sciences, a drug delivery Contract Development and Manufacturing Organization, announced that they have entered into an exclusive agreement with Actavis plc, a leading specialty pharmaceutical company, to develop an unnamed complex generic product. Actavis will have responsibi
4/19/14 - Some generic drugs have had eye-popping price spikes [Fort Worth Star-Telegram :: ]
April 19 Pharmacist Larry Cowan can flip through his records and spot the generic drugs that have taken big price jumps in the past year or so. "Now the price is close to 10 times that," said Cowan, owner of Glenview Professional Pharmacy in Richland Hills. While the FDA in the past month removed doxycyline from its shortage list, it still costs
4/19/14 - Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE Patent Due to the Potential for the Company to Recover Patent Infringement Damages
Teva Pharmaceutical Industries Ltd. announced that while the Chief Justice of the United States found that Teva had demonstrated a fair prospect of success on the merits in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Teva will continue pursuing its appeal in the S
4/18/14 - AmpliPhi to Present at 13th Annual Needham Healthcare Conference
By a News Reporter-Staff News Editor at Drug Week AmpliPhi BioSciences Corporation., the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that Philip Young, President and CEO, will be presenting a corporate overview at the 13th Annual Needham Healthcare Conference on Tue
4/18/14 - BioPharm America 2014 to Returns to Boston's Copley Place [Health & Beauty Close - Up]
Produced by EBD Group in collaboration with the Massachusetts Biotechnology Council, the September 22-24 event will bring the global life science industry to Boston to facilitate strategic collaborations with leading companies. AstraZeneca, Bayer HealthCare, Bristol Myers Squibb, EMD Serono, Novo Nordisk, and Shire are just a few large drug develop
4/18/14 - Boston Scientific Receives FDA Approval of New Defibrillators and Heart Failure Devices [Professional Services Close - Up]
Boston Scientific Corp. has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. These newly approved devices continue the Boston Scientific history of projected longevity and a six-year CRT-D warranty. Extending the Boston Scientific portfolio of defibrillators, the ICDs in t
4/18/14 - Cellceutix Study Shows Cellceutix Antibiotic Active Against Drug- Resistant Superbug Klebsiella Pneumoniae [Professional Services Close - Up]
Cellceutix Corp., a clinical stage biopharmaceutical company developing therapies in oncology, dermatology, and antibiotic applications, reports favorable results in a recently completed preclinical study evaluating its novel antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae. According to a release, in a...
4/18/14 - Court declines to block drug ruling in patent case
WASHINGTON The Supreme Court has declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals. Teva claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug. That ruling allows rivals Mylan Inc., Momenta Pharma
4/18/14 - FDA approves Ragwitek for short ragweed pollen allergies
Release date- 17042014- The U.S. Food and Drug Administration today approved Ragwitek, the first allergen extract administered under the tongue to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis, in adults 18 years through 65 years of age. 'The approval of Ragwitek offers millions of adults living with ragweed p
4/18/14 - FDA official: Agency is committed to timely approval of vaccines [Examiner, The (Washington, DC)]
FDA is committed both to responding rapidly to public health threats and to approving products for serious medical conditions in a timely manner. In addition, the approval of any vaccine in the United States requires submission of a Biologics License Application to the FDA by a manufacturer so that the FDA can review the vaccine's safety and effect
4/18/14 - FDB to Present Drug Pricing Analysis Poster Comparing AWP and WAC to AAC Benchmarks
By a News Reporter-Staff News Editor at Insurance Weekly News FDB, the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes, announced that it will present a poster at the Academy of Managed Care Pharmacy 26th Annual Meeting, April 1- 4, 2014, in Tampa, Florida and the International Soci
4/18/14 - Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Targeted Medical Pharma Completes Middle East Distribution Agreement
Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. "These positive results have propelled the enrollment of the second cohort with strong participation across our clinical trial sites. In 2013, Galectin Therapeutics received Fast Track designation from the FDA for this clinical development..
4/18/14 - GlaxoSmithKline Assigned Patent for Tetrahydroquinoline Derivatives and Their Pharmaceutical Use
ALEXANDRIA, Va., April 18 GlaxoSmithKline, Philadelphia, has been assigned a patent developed by seven co-inventors for "tetrahydroquinoline derivatives and their pharmaceutical use." The co-inventors are Emmanuel Hubert Demont, Stevenage, United Kingdom, Neil Stuart Garton, Stevenage, United Kingdom, Romain Luc Marie Gosmini, Les Ulis, France, T
4/18/14 - OMICS Group BABE-2014 Summit to Revolutionize the Next Generation Medicines
Organizing Committee Members Include: Wolfgang Sadee, The Ohio State University, USA; Diane J Burgess, University of Connecticut, USA; Lakshmi Putcha, NASA, USA; Sean Zhang, Sino-American Pharmaceutical Professionals Association, USA; Mirko Diksic, McGill University, Canada; Mohammad Khalid Parvez, King Saud University, Saudi Arabia;. OMICS Group o
4/18/14 - PanOptica Secures $45 Million to Finance Clinical Development of Anti-VEGF Eye Drop for Wet AMD [Health & Beauty Close - Up]
PanOptica, Inc., a private biopharmaceutical company focusing on licensing and developing ophthalmology therapies, announced that it has raised up to $45 million in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically small-molecule selective inhibitor of VEGF signaling being investigated as a topi
4/18/14 - Patent Issued for Pharmaceutical Formulations of Modafinil
By a News Reporter-Staff News Editor at Health& Medicine Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Heacock, Craig S.; Parikh, Alpa B.; Patel, Piyush R., filed on August 21, 2012, was published online on April 1, 2014. The patent's assignee for patent number 8686047 is Cephalon, Inc.. No. 4,177,290, a
4/18/14 - Patent Issued for Use of Amisulpride as an Anti-Emetic
By a News Reporter-Staff News Editor at Drug Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Gilbert, Julian Clive; Gristwood, Robert William; Cooper, Nicola; Fox, Gabriel, filed on July 26, 2012, was published online on April 1, 2014. The patent's assignee for patent number 8686019 is Acacia Pharma Limite
4/18/14 - Prime Therapeutics study finds high risk opioid users have medical costs three times higher than other opioid users
By a News Reporter-Staff News Editor at Insurance Weekly News People who are at high-risk for opioid abuse use had significantly higher total medical costs than those who were not at high risk according to a new study by Prime Therapeutics. The Centers for Medicare& Medicare Services defines high risk as "using a daily morphine equivalent dose of
4/18/14 - SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against The Medicines Company and Certain Officers - MDCO
Pomerantz LLP has filed a class action lawsuit against The Medicines Company and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 2:33- av-00001, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Medicines securities between F
4/18/14 - Teva Introduces Generic Lunesta Tablets in the United States [Professional Services Close - Up]
Teva Pharmaceutical Industries announced the launch of the generic equivalent to Lunesta, 1, 2 and 3 mg, in the United States. According to a release, Lunesta Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013. Teva Pharmaceutical Industries i
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
An Overview of Complementary and Alternative Medicine
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement